Synergy Pharmaceuticals Inc. (SGYP) Reaches $2.08 After 9.00% Up Move; Last Week Honda Motor Co., Ltd. (HMC) Analysts

February 15, 2018 - By Stephen Andrade

The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) is a huge mover today! The stock increased 1.22% or $0.025 during the last trading session, reaching $2.075. About 1.01M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since February 15, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.The move comes after 7 months positive chart setup for the $511.82M company. It was reported on Feb, 15 by Barchart.com. We have $2.26 PT which if reached, will make NASDAQ:SGYP worth $46.06M more.

Among 9 analysts covering Honda Motor Co (NYSE:HMC), 2 have Buy rating, 5 Sell and 2 Hold. Therefore 22% are positive. Honda Motor Co had 20 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was downgraded by CLSA to “Underperform” on Friday, May 13. The rating was maintained by Jefferies on Tuesday, August 15 with “Buy”. Nomura downgraded the shares of HMC in report on Friday, May 13 to “Reduce” rating. The company was downgraded on Friday, May 13 by Credit Agricole. The company was maintained on Monday, May 29 by Jefferies. The stock has “Buy” rating by Jefferies on Friday, May 13. Susquehanna initiated Honda Motor Co., Ltd. (NYSE:HMC) on Tuesday, December 22 with “Neutral” rating. The stock of Honda Motor Co., Ltd. (NYSE:HMC) has “Sell” rating given on Friday, May 27 by UBS. The firm has “Buy” rating given on Tuesday, July 4 by Jefferies. The stock has “Buy” rating by Jefferies on Friday, November 10. See Honda Motor Co., Ltd. (NYSE:HMC) latest ratings:

10/11/2017 Broker: Jefferies Rating: Buy New Target: $40.45 Maintain
12/10/2017 Broker: Jefferies Rating: Buy New Target: $36.36 Maintain
18/09/2017 Broker: Jefferies Rating: Buy New Target: $34.55 Maintain

The stock increased 0.44% or $0.15 during the last trading session, reaching $35.22. About 396,077 shares traded. Honda Motor Co., Ltd. (NYSE:HMC) has risen 4.10% since February 15, 2017 and is uptrending. It has underperformed by 12.60% the S&P500.

Honda Motor Co., Ltd. develops, manufactures, and distributes motorcycles, automobiles, power products, and other products worldwide. The company has market cap of $61.95 billion. The firm operates through four divisions: Motorcycle Business, Automobile Business, Financial Services Business, and Power Product and Other Businesses. It has a 6.61 P/E ratio. The Motorcycle Business segment produces sports models, including trial and moto-cross racing vehicles; business and commuter models; all-terrain vehicles; and side-by-side models.

Investors sentiment increased to 1.9 in Q3 2017. Its up 0.41, from 1.49 in 2017Q2. It improved, as 16 investors sold Synergy Pharmaceuticals Inc. shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Barclays Public Ltd Co holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 29,666 shares. Creative Planning invested 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Schwab Charles Inv Management holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 945,186 shares. Valley Advisers holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 4,000 shares. Equitec Specialists Lc accumulated 0% or 3,000 shares. Group has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Natl Planning Corporation stated it has 10,000 shares. Sg Americas Lc holds 0% or 38,232 shares. Lehman Financial Resources stated it has 0.02% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Jane Street Grp Inc Ltd Co, New York-based fund reported 196,976 shares. 355,043 are held by Parametric Port Associate Limited Liability Company. First Tru L P reported 13,210 shares. Amalgamated Bank & Trust, a New York-based fund reported 29,061 shares. The Connecticut-based Cubist Systematic Strategies Ltd Liability has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). California-based Malaga Cove Cap has invested 0.01% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP).

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 40 analyst reports since August 25, 2015 according to SRatingsIntel. As per Thursday, November 9, the company rating was maintained by Cantor Fitzgerald. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by H.C. Wainwright on Wednesday, October 11. Citigroup maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Wednesday, September 13 with “Sell” rating. Citigroup downgraded the stock to “Sell” rating in Thursday, April 6 report. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, January 25 report. Cantor Fitzgerald maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Wednesday, August 9. Cantor Fitzgerald has “Buy” rating and $1100 target. H.C. Wainwright maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Thursday, February 1 with “Buy” rating. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Friday, January 20. Rodman & Renshaw has “Buy” rating and $18 target. The company was maintained on Wednesday, June 7 by Cantor Fitzgerald. On Monday, June 26 the stock rating was maintained by BTIG Research with “Buy”.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $511.82 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on March, 7. They expect $-0.20 earnings per share, up 35.48% or $0.11 from last year’s $-0.31 per share. After $-0.22 actual earnings per share reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Stephen Andrade

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: